Disease impact on the quality of life of children with inflammatory bowel disease

Table 1 Demographic data, disease characteristics and medications at the time of the evaluation n (%)

	Overall (n = 99)	CD (n = 62)	UC (n = 37)	P value
Gender, females	59 (59.6)	32 (51.6)	27 (73.0)	0.063
Age (yr)	12.8 ± 2.6	13.4 ± 2.4	11.6 ± 2.5	0.0011
Age at diagnosis (yr)	9.9 ± 3.1	10.7 ± 2.9	8.6 ± 3.0	< 0.0011
Number of hospitalizations4	2 (1-4)	2 (1-4)	3 (1-6)	0.092
Disease duration at IMPACT completion (yr)	2.8 ± 2.6	2.7 ± 2.5	3.0 ± 2.7	0.481
Disease activity	NA	7.2 ± 10.3	14.0 ± 20.5	NA
Disease status, in remission	70 (70.7)	45 (72.6)	25 (67.6)	0.653
Physician global assessment				0.93
Clinical remission	80 (80.8)	50 (80.6)	30 (81.1)
Mild	14 (14.1)	9 (14.5)	5 (13.5)
Moderate	5 (5.1)	3 (4.8)	2 (5.4)
Medications at IMPACT completion
Antibiotics	2 (2.0)	2 (3.2)	0 (0.0)	0.523
Steroids	39 (39.4)	24 (38.7)	15 (40.5)	0.993
Immunomodulators	68 (68.7)	47 (75.8)	21 (56.8)	0.113
Biologic agents	31 (31.3)	25 (40.3)	6 (16.2)	0.033
Enteral nutrition	0 (0.0)	0 (0.0)	0 (0.0)	NA
Aminosalicylates	52 (52.5)	15 (24.2)	37 (100.0)	< 0.0013

¹t-test;

²Mann-Whitney test;

³Fisher’s exact test;

⁴Three months prior to completing IMPACT, median (interquartile range). NA: Not applicable; CD: Crohn’s disease; UC: Ulcerative colitis.